Correlation Between Prostatype Genomics and Devyser Diagnostics

Can any of the company-specific risk be diversified away by investing in both Prostatype Genomics and Devyser Diagnostics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Prostatype Genomics and Devyser Diagnostics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Prostatype Genomics AB and Devyser Diagnostics AB, you can compare the effects of market volatilities on Prostatype Genomics and Devyser Diagnostics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Prostatype Genomics with a short position of Devyser Diagnostics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Prostatype Genomics and Devyser Diagnostics.

Diversification Opportunities for Prostatype Genomics and Devyser Diagnostics

-0.66

Correlation Coefficient

Prostatype Genomics  Devyser Diagnostics

Excellent diversification

The 3 months correlation between Prostatype and Devyser is -0.66. Overlapping area represents the amount of risk that can be diversified away by holding Prostatype Genomics AB and Devyser Diagnostics AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Devyser Diagnostics and Prostatype Genomics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Prostatype Genomics AB are associated (or correlated) with Devyser Diagnostics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Devyser Diagnostics has no effect on the direction of Prostatype Genomics i.e., Prostatype Genomics and Devyser Diagnostics go up and down completely randomly.

Pair Corralation between Prostatype Genomics and Devyser Diagnostics

Assuming the 90 days trading horizon Prostatype Genomics AB is expected to under-perform the Devyser Diagnostics. In addition to that, Prostatype Genomics is 4.7 times more volatile than Devyser Diagnostics AB. It trades about -0.03 of its total potential returns per unit of risk. Devyser Diagnostics AB is currently generating about 0.04 per unit of volatility. If you would invest  11,350  in Devyser Diagnostics AB on April 21, 2025 and sell it today you would earn a total of  2,010  from holding Devyser Diagnostics AB or generate 17.71% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Prostatype Genomics AB  vs.  Devyser Diagnostics AB

Prostatype Genomics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Prostatype Genomics AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Devyser Diagnostics

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Devyser Diagnostics AB are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Devyser Diagnostics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Prostatype Genomics and Devyser Diagnostics

The main advantage of trading using opposite Prostatype Genomics and Devyser Diagnostics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Prostatype Genomics position performs unexpectedly, Devyser Diagnostics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Devyser Diagnostics will offset losses from the drop in Devyser Diagnostics' long position.

The idea behind Prostatype Genomics AB and Devyser Diagnostics AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.